A few weeks ago, the DEA released an internal directive on the presence of cannabinoids in products and materials made from the cannabis plant, stating that “the mere presence of cannabinoids is not itself dispositive as to whether a substance is within the scope of the CSA.” Arnaud Dumas de Rauly, co-founder & co-CEO, of The Blinc Group, a distribution-centric vapor and cannabis incubator, wonders whether there has been pushback or pressure on Patterson following that announcement. Also, Patterson has stated in the past that ‘The reason why [cannabis] remains in Schedule I is the science,’” Dumas de Rauly said. “The lack of federally approved grow facilities—the Justice Department, headed by Jeff Sessions, hasn’t approved any of the more than two dozen proposals for new grow sites—makes gaining access to cannabis to run clinical trials exceptionally challenging thus impending the DEA’s ability to change its stance.